Immune-related adverse events in melanoma patients <65 and >65 treated with nivolumab.
irAE
Incidence (%) Age <65
Incidence (%) Ageā„65
p-value
Rash
38.5
40.4
0.966
Diarrhea
30.2
21.2
0.322
Vitilligo
10.4
7.7
0.805
Hypothyroidism
8.3
5.8
0.811
Muscositis
5.2
5.8
0.99
Myalgias
4.2
0
0.336
Pneumonitis
1.1
1.9
0.99